Cocrystal Pharma (COCP) Operating Leases (2019 - 2026)

Cocrystal Pharma (COCP) has 8 years of Operating Leases data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed 0.0% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (changed 0.0% YoY), and the FY2025 full-year result was $1.2 million, down 22.19% from the prior year.
• Operating Leases advanced to $1.4 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.9 million in Q3 2024 to a low of $10000.0 in Q2 2023.
• A 5-year average of $1.0 million and a median of $1.4 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 97.49% in 2023 and surged 15190.0% in 2024, its largest moves.
• Tracing COCP's Operating Leases over 5 years: stood at $57000.0 in 2022, then soared by 2729.82% to $1.6 million in 2023, then slipped by 6.7% to $1.5 million in 2024, then declined by 22.19% to $1.2 million in 2025, then climbed by 21.61% to $1.4 million in 2026.
• Business Quant data shows COCP's Operating Leases at $1.4 million in Q1 2026, $1.2 million in Q4 2025, and $1.6 million in Q3 2025.